Sonnet BioTherapeutics Holdings, Inc. Gains 48.29%

Mon, Aug 24, 2020 at 05:30 PM

Sonnet BioTherapeutics Holdings, Inc. (SONN:NASDAQ) rocketted at $3.9, representing a gain of 48.3%. On Fri 21 Aug 20, SONN:NASDAQ touched a New 2-Week Intraday Low of $2.4. The stock got featured on our News Catalysts scanner on Mon 24 Aug 20 at 11:28 AM in the 'BIOTECH' category. From Fri 07 Aug 20, the stock recorded 20.00% Up Days and 27.27% Green Days

The stock spiked on Fri 31 Jul 20 at $7.89 with a volume of 131M+, and its share price has been moving sideways in recent weeks.

About Sonnet BioTherapeutics Holdings, Inc. (SONN:NASDAQ)

Sonnet BioTherapeutics Holdings Inc is a biotechnology company engaged in the development of biologic drugs focused on human antibody binding technology. The firm's pipeline products include SON-080 (low-dose IL-6), SON-081 (low dose IL-6), SON-1010 (IL12-FHAB), and others.

Top 10 Gainers:

Cancer Genetics, Inc. (CGIX:NASDAQ), 114.78%
Sonnet BioTherapeutics Holdings, Inc. (SONN:NASDAQ), 48.29%
Borqs Technologies, Inc. (BRQS:NASDAQ), 39.46%
Tortoise Acquisition Corp. (SHLL:NYSE), 33.73%
iBio, Inc. (IBIO:NYSEMKT), 30%
TravelCenters of America Inc. (TA:NASDAQ), 29.61%
VivoPower International PLC (VVPR:NASDAQ), 25.57%
CNS Pharmaceuticals, Inc. (CNSP:NASDAQ), 24.86%
Gulfport Energy Corporation (GPOR:NASDAQ), 24.18%
AutoWeb, Inc. (AUTO:NASDAQ), 24.1%